Comparative Study Of Different Marketed Preparation

Abstract

This Study’s Goal Is To Perform In-vitro Quality Control Testing On Diclofenac Sodium Tablets Using The Disintegration And Dissolving Test, Drug Assay, Weight Variation Test, And Friability Test. In The Trial, Two Brands Of Diclofenac Sodium Tablets—Brand A And Brand B—were Used. According To The Findings Of Quality Control (QC) Tests, Both Brand A And Brand B Of Diclofenac Sodium Tablets Meet USP Requirements. Regarding Weight Variation, Brands A And B Have Variances Of 2.79% And 2.05% Above The Mean Weight Limit, Respectively. Within The 10% USP Standard Limits, The Lower Mean Weight Limit Variances Are 1.21% And 1.27%, Respectively.According To Friability Testing, Brands A And B Had Average Friability Of 0.062% And 0.01% Mass Loss, Respectively, Falling Within The USP’s 1% Mass Loss Restrictions. Regarding Medication Assay, Brands A And B Both Fall Within The 85%–115% USP Range, Respectively. According To The Disintegration Test, Brands A And B Fall Inside A 15-minute Time Interval Segment; Their Respective Disintegration Times Are 6.69 And 7.02 Minutes. Within A 45-minute Test Period, The Medication Dissolution Percentage For Brand B Of Diclofenac Sodium Was 90.7%. The Pharmacopoeia Limits Established By The USP Standards Are Met By Brands A And B. According To The Friability Test, Both Brands A And B’s Mass Loss Fell Within The Acceptable Range Of 1%. Comparably, Both Brands Fall Within The Typical Range Of 10% Above Or Below The Mean Weight In Terms Of Weight Variation. The Medication Availability For Both Brands Fell Within The Designated 85%–115% Standard Range, According To The Drug Assay. They Completed The Dissolution And Disintegration Tests In Less Than 45 And 15 Minutes, Respectively.

Keywords